July 15 (Reuters) - ** Sun Pharma SUN.NS, India's top drugmaker by revenue, launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp INCY.O
** Shares up 0.6%; pharma index .NIPHARM trading flat
POTENTIAL $1 BLN OPPORTUNITY
** Nuvama ("hold"; PT: 1,830 rupees) estimates $300-$400 mln annual sales from Leqselvi by FY30, with peak sales potential of $1 bln in future
** Sees Leqselvi becoming U.S. blockbuster drug for co
** Morgan Stanley ("overweight"; PT: 1,960 rupees) says Leqselvi's commercialisation in U.S. includes "aggressive" patient support programme, indicating Sun Pharma's intent to drive early adoption amid competition from Pfizer PFE.N, Eli Lilly LLY.N
** Elara Capital ("accumulate"; PT: 1,871 rupees) sees Leqselvi becoming Sun Pharma's second-largest product
** Says that with limited treatment options, innovative drugs like Leqselvi remain important